Fontan相关蛋白丢失性肠病与心脏移植预后:多中心研究
PLE严重程度、病程及治疗与移植后死亡无关,但免疫抑制方案与死亡率相关,且PLE在几乎所有存活者中缓解。
要点
- PLE病程、住院频率、白蛋白替代及治疗强度均与心脏移植后死亡无关联。
- 标准霉酚酸酯免疫抑制在存活者中使用率95%,非存活者仅44%(p=0.03)。
- 移植后存活者中除1例外PLE均完全缓解,中位缓解时间1个月。
核心结论
- PLE严重程度、病程和治疗不影响心脏移植后结局,但免疫抑制方案可能影响生存。
- PLE在几乎所有移植后存活者中缓解,且缓解不受PLE特异性因素影响。
研究设计与样本
- 收集人口学、内科、外科、导管检查及PLE特异性数据(病程、治疗强度、住院和并发症)。
- 68例进入等待名单,52例接受心脏移植。
主要发现
- 52例接受心脏移植者术后1个月生存率92%,1年生存率83%。
- 68例等待者中8例因病情恶化移除,4例等待中死亡,4例仍在等待。
- 移植后排斥反应发生率53%,感染发生率42%,均与PLE特异性因素无关。
- PLE在除1例外的所有移植后存活者中完全缓解,中位缓解时间1个月(四分位距1至3个月)。
关键数值与推荐
- 标准霉酚酸酯免疫抑制在存活者中使用率为95%,在非存活者中为44%(p=0.03)。
- PLE病程、移植前住院、白蛋白替代需求/频率、PLE治疗及生长参数均与移植后死亡率无关联。
临床怎么用
- 对Fontan相关PLE患者进行心脏移植评估时,PLE严重程度和病程不应作为排除标准。
- 移植后免疫抑制方案的选择可能影响生存,标准霉酚酸酯方案与更高生存率相关。
- 移植后需监测PLE缓解情况,多数存活者在中位1个月内完全缓解。
局限性
- 回顾性多中心设计,各中心样本量小(中位5例/中心)。
- 原文未报告免疫抑制方案与生存关联的具体机制及多变量校正结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The influence of Fontan-associated protein-losing enteropathy's (PLE) severity, duration, and treatment on heart transplant (HTx) outcomes is unknown. We hypothesized that long-standing PLE and PLE requiring more intensive therapy are associated with increased post-HTx mortality. METHODS: This 12-center, retrospective cohort study of post-Fontan patients with PLE referred for HTx from 2003 to 2015 involved collection of demographic, medical, surgical, and catheterization data, as well as PLE-specific data, including duration of disease, intensity/details of treatment, hospitalizations, and complications. Factors associated with waitlist and post-HTx outcomes and PLE resolution were sought. RESULTS: Eighty patients (median of 5 per center) were referred for HTx evaluation. Of 68 patients listed for HTx, 8 were removed due to deterioration, 4 died waiting, and 4 remain listed. In 52 patients undergoing HTx, post-HTx 1-month survival was 92% and 1-year survival was 83%. PLE-specific factors, including duration of PLE pre-HTx, pre-HTx hospitalizations, need for/frequency of albumin replacement, PLE therapies, and growth parameters had no association with post-HTx mortality. Immunosuppressant regimen was associated with mortality; standard mycophenolate mofetil immunotherapy was used in 95% of survivors compared with only 44% of non-survivors (p = 0.03). Rejection (53%) and infection (42%) post-HTx were common, but not associated with PLE-specific factors. PLE resolved completely in all but 1 HTx survivor at a median of 1 month (interquartile range 1 to 3 months); resolution was not affected by PLE-specific factors. CONCLUSIONS: PLE severity, duration, and treatment do not influence post-HTx outcome, but immunosuppressive regimen may have an impact on survival. PLE resolves in nearly all survivors.
引用
- Schumacher KR, Yu S, Butts R, et al. Fontan-associated protein-losing enteropathy and post‒heart transplant outcomes: A multicenter study. J Heart Lung Transplant. 2018. PMID: 30391195. doi:10.1016/j.healun.2018.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。